Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754870 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL9543062 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL3406853 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL23665084 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL19770394 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL23665088 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL1527010 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL7753936 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL22779020 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL17679207 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-01-18 | — | — | US | disclosed |
| US-20170119902-A1 | ANTIBODY-DRUG CONJUGATE (ADC) AND METHOD FOR FORMING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | SLC43A1, HCAR3, SLC7A1 | FUCA1 2191/4885CA2 1440/4885CA9 739/4885 |
| US-20170119902-A1 | ANTIBODY-DRUG CONJUGATE (ADC) AND METHOD FOR FORMING THE SAME | DNPEP, DLST, DDOST | FUCA1 345/4885CA2 1425/4885CA9 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.